Supplemental Table from Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Supplementary Table 1. Toxicities during the first cycle of FOLFIRI plus bevacizumab. Number of patients (%) is indicated. Toxicities were included if they occurred in at least 10% of patients or if they were grade 3 or greater, and if they were at least possibly related to treatment.</p

supplemental figure from Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Supplementary Figure 1. Progression-free survival (PFS) overall (A), by UGT1A1 genotype (B), and by irinotecan dose (C).</p